Core Viewpoint - The announcement confirms the appointment of Mr. Zhang as a director of Industrial Bank, effective September 2, 2025, following approval from the National Financial Regulatory Administration [1]. Company Summary - Industrial Bank received official approval for Mr. Zhang's directorship from the National Financial Regulatory Administration [1]. - Mr. Zhang's qualifications and background can be found in a previous announcement published on May 31, 2024, on the Shanghai Stock Exchange website [1].

Group 1 - The core viewpoint of the news is the acquisition of Nanjing Steel Co., Ltd. by Taifu Special Steel (Jiangsu) Co., Ltd., with Citic Securities acting as the financial advisor for the transaction [1][2] - The acquisition involves the transfer of 55.2482% equity of Nanjing Steel Group from Hubei Xinye Steel Co., Ltd. to Jiangsu Special Steel, resulting in Jiangsu Special Steel holding 59.10% of Nanjing Steel Co., Ltd. after the transaction [2][3] - The financial advisor confirms that during the continuous supervision period, both the acquirer and the target company have complied with relevant laws and regulations, and there are no violations of corporate governance rules [3][4] Group 2 - Jiangsu Special Steel and its controlling shareholder, Changyue Investment, have made commitments to maintain the independence of Nanjing Steel Co., Ltd. post-acquisition, ensuring no improper benefits are sought [3][4] - The acquirer has also committed to avoiding any substantial competition with Nanjing Steel Co., Ltd. and has outlined measures to prevent such competition [4][5] - The financial advisor has verified that the commitments regarding independence and competition have been strictly adhered to during the supervision period [5][6] Group 3 - There are no plans to change the main business operations of Nanjing Steel Co., Ltd. within the next 12 months, and no significant adjustments to its assets or business are anticipated [8][9] - The acquirer has no plans to adjust the board of directors or senior management of Nanjing Steel Co., Ltd. during the supervision period [9][10] - There are no proposed changes to the company's articles of association or significant alterations to employee hiring practices [10][12] Group 4 - The financial advisor has found no instances of Nanjing Steel Co., Ltd. providing guarantees or loans to the acquirer or its affiliates that would harm the interests of the company [12][13] - Overall, the financial advisor concludes that the acquirer and its affiliates have fulfilled their reporting and announcement obligations, and there are no violations of public commitments [13]

Core Viewpoint - The company aims to enhance its operational efficiency and market share through digital transformation, AI integration, and strategic investments while navigating challenges in the pharmaceutical wholesale sector due to regulatory pressures and market dynamics [1][2][3]. Group 1: Company Performance - In the first half of 2025, the company reported a revenue of 10.301 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 430 million yuan, down 7.52% compared to the previous year [1]. - The decline in performance is attributed to stricter control over drug expenditure by medical institutions and the impact of centralized procurement policies, leading to reduced sales and profit margins in the pharmaceutical wholesale business [1][6]. - The company is optimistic about gradually recovering growth through product structure optimization and the development of retail, industrial, and innovative business segments [1]. Group 2: AI and Digital Transformation - The company has implemented AI technologies in various areas, including supply chain management, hospital diagnostics, and retail health services, to enhance operational efficiency and customer engagement [2][3]. - AI applications include intelligent warehousing systems, patient management tools, and a digital health service model that integrates healthcare professionals to provide comprehensive patient care [2][3]. Group 3: Product Development and Market Expansion - The company is actively expanding its product lines in traditional Chinese medicine, with significant progress in the registration of traditional Chinese medicine granules and the establishment of partnerships with hospitals across multiple provinces [4]. - The company aims to increase the proportion of sales from traditional Chinese medicine granules outside its home province to 50% within 1 to 2 years [4]. Group 4: Financial Management and Cash Flow - The company has seen a year-on-year increase of 78.07% in net cash flow from operating activities, indicating improved cash management despite challenges in accounts receivable [5]. - The company is focusing on enhancing the quality of sales and improving cash flow by tightening control over accounts receivable and prioritizing high-quality customer relationships [5]. Group 5: Strategic Initiatives - The company has launched stock option and employee stock ownership plans to align employee interests with corporate goals, particularly focusing on the industrial sector's growth potential [8]. - The performance metrics for these plans emphasize net profit growth and the balance between operating cash flow and net profit, aiming to enhance operational safety and employee motivation [8].

Core Viewpoint - The announcement details the upcoming expiration of the first lock-up period and additional lock-up period for the company's 2024 employee stock ownership plan, along with the conditions for unlocking shares based on performance metrics [1][4]. Group 1: Employee Stock Ownership Plan Details - The first lock-up period for the 2024 employee stock ownership plan will end on September 6, 2025, with an additional lock-up period following it [1]. - The plan includes a total of 150,000,072 shares transferred to the employee stock ownership plan as of March 5, 2024 [2]. - The first lock-up period is defined as 12 months from the last stock transfer date, while the additional lock-up period lasts for 6 months after the first period [4]. Group 2: Performance Metrics and Unlocking Conditions - The unlocking conditions are based on company performance metrics, including cumulative operating income and net profit for the renewable energy sector [5][6]. - The target values for the first unlocking period are set at 3.18 billion for operating income and 23.0881 million for net profit, with corresponding thresholds for unlocking shares [5]. - The company achieved a cumulative net profit of 26.0562 million, resulting in a 94% unlocking ratio for the first lock-up period [6]. Group 3: Individual Performance Assessment - Individual performance assessments will determine the final number of shares unlocked for each participant, with performance grades ranging from A (100% unlock) to D (0% unlock) [6][7]. - Two participants achieved a performance grade of B, resulting in an 80% unlocking coefficient, while one participant received a grade of C, leading to a 60% unlocking coefficient [7]. Group 4: Future Arrangements - After the expiration of the lock-up periods, the company will decide whether to sell the unlocked shares based on market conditions and the employee stock ownership plan's guidelines [8]. - The company commits to adhering to market trading rules and relevant regulations regarding stock transactions [8].

Group 1 - The company announced the resignation of non-independent director Sun Menghui due to personal reasons, who will continue as a brand creative consultant [1][2] - The board of directors approved the proposal to elect a new non-independent director, Niu Zhentian, to ensure the normal operation of the board [2] - Niu Zhentian has held various management positions within the company since 2018 and is currently the assistant to the chairman [5] Group 2 - Sun Menghui indirectly holds 37,229,484 shares of the company, accounting for a significant portion of the total share capital [2] - The board expressed gratitude for Sun Menghui's contributions during her tenure [2] - Niu Zhentian meets all legal and regulatory requirements for the position and is not involved in any legal violations [5]

Core Viewpoint - Jiangsu Libat Co., Ltd. has completed the cancellation of its supervisory board, changed its business scope, and revised its articles of association, as approved in the board meeting and the first extraordinary shareholders' meeting of 2025 [1][2] Group 1: Company Changes - The company held its 17th meeting of the fifth board on August 8, 2025, and the first extraordinary shareholders' meeting on August 25, 2025, to approve the cancellation of the supervisory board and changes to the business scope [1] - The company has completed the industrial and commercial change registration and obtained a new business license from the Suzhou Market Supervision Administration [1] Group 2: Business Information - The registered capital of Jiangsu Libat Co., Ltd. is RMB 449.07 million, and it is classified as a joint-stock company with Hong Kong, Macao, and domestic investment [1] - The company’s business scope includes special equipment design, manufacturing, installation, and repair, as well as civil nuclear safety equipment and road cargo transportation [1] - The company is involved in various sectors, including marine engineering design, oil and gas technology services, and renewable energy technology research [2]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for Amlodipine Besylate Tablets from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][2]. Drug Registration Details - The drug registered is Amlodipine Besylate Tablets, available in dosages of 5mg and 10mg, classified as a chemical drug of category 4, and is a prescription medication [1][2]. - The sales revenue for Amlodipine Besylate Tablets in hospitals across China reached 1.216 billion yuan in 2024 [2]. R&D Investment and Production - As of the announcement date, the R&D investment for Amlodipine Besylate Tablets by Changle Pharmaceutical is approximately 3.83 million yuan (unaudited) [2]. - Changle Pharmaceutical has obtained four production licenses for the drug as of the announcement date [2]. Impact on the Company - The acquisition of the Drug Registration Certificate is expected to enrich the product line of the company and its subsidiaries, thereby enhancing their market competitiveness [2]. - The impact on the company's recent operating performance is not expected to be significant [2].

证券代码：002855 证券简称：捷荣技术 公告编号：2025-046 东莞捷荣技术股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 东莞捷荣技术股份有限公司（以下简称"公司"）董事会近日收到康凯先生 提交的书面辞职报告，由于公司调整原因，康凯先生申请辞去公司第四届董事会 董事职务，同时一并辞去董事会专门委员会委员职务，辞职后，其仍在公司担任 其他职务。根据《公司法》《公司章程》等相关法律法规规定，康凯先生的辞职 不会导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作， 辞职报告自送达董事会之日起生效，公司将根据《公司章程》等相关规定，尽快 完成董事的补选工作。 截至本公告披露日，康凯先生直接持有捷荣技术股份 256,600 股，占公司总 股本的 0.1041%。康凯先生不存在应当履行而未履行的承诺事项，其股份变动将 严格遵守《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高 级管理人员减持股份》、《深圳证券交易所上市公司自律监管指引第 10 号—— 股份变动管理》等法律法规及规范性文件的相关规定。 康凯先生担任公司董 ...

Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue 73,966,642 A-shares at a price of RMB 13.79 per share, raising a total of RMB 1,019,999,993.18, with a net amount of RMB 1,009,449,486.02 after deducting issuance costs [1][2] Fund Management Agreement - A four-party supervision agreement for the special fundraising account has been signed between the company, its wholly-owned subsidiary, the sponsor, and the bank to ensure proper management and usage of the raised funds [1][2] - The funds will be specifically used for the digital R&D and manufacturing capability construction project of precision-guided products [2][3] Cash Management Provisions - The company is allowed to temporarily store idle funds in cash management products, provided that these do not affect the normal investment plans of the raised funds [3][4] - The bank is required to provide monthly updates on the status of the cash management products to the sponsor [4] Compliance and Oversight - The sponsor is responsible for ongoing supervision of the fundraising management in accordance with relevant regulations and guidelines [4][5] - Any changes in the sponsor's representatives must be communicated to all parties involved, ensuring transparency and compliance [5][6] Dispute Resolution - Any disputes arising from the agreement will be resolved through arbitration in Beijing, with the arbitration conducted in Chinese [6]

Core Viewpoint - Shenzhen Inovance Technology Co., Ltd. has announced the commencement of the second exercise period for its sixth stock option incentive plan, allowing 225 eligible participants to exercise a total of 371,727 stock options at a price of 59.90 yuan per option [1][2]. Group 1: Stock Option Details - The stock options available for exercise are priced at 59.90 yuan each, with a total of 371,727 options available for 225 eligible participants, representing 0.0138% of the company's total share capital [1]. - The exercise of stock options will be subject to adjustments in case of dividends, capital increases, stock splits, or other corporate actions [2]. - The exercise must occur within the specified period, and any unexercised options will automatically expire [2]. Group 2: Financial Impact - The company will recognize the fair value of the stock options based on the closing price on the grant date, and will adjust the expected number of exercisable options based on performance indicators and actual exercise numbers [2][3]. - If all options are exercised, the total share capital will increase by 371,727 shares, which may dilute the earnings per share but will not significantly impact the company's financial condition or operational results [2]. Group 3: Fund Utilization and Tax Arrangements - Funds raised from the exercise of stock options will be used to supplement the company's working capital [3]. - The individual income tax obligations of the participants will be borne by them, with the company responsible for withholding and remitting the relevant taxes according to national tax regulations [3]. Group 4: Additional Information - The company will provide updates on the exercise status, changes in incentive participants, adjustments to stock option parameters, and any changes in share distribution resulting from the exercise [3].